Early persistent hyperparathyroidism post-renal transplantation as a predictor of worse graft function and mortality after transplantation.
Journal
Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
15
07
2020
revised:
19
08
2020
accepted:
27
08
2020
pubmed:
20
9
2020
medline:
24
6
2021
entrez:
19
9
2020
Statut:
ppublish
Résumé
Persistent hyperparathyroidism (pHPT) is frequently seen after transplantation contributing to post-transplant complications. We conducted a retrospective single center analysis to explore the relationship of early pHPT and long-term allograft outcome. Patients were divided into high (N = 153) and low (N = 252) PTH groups based on serum parathyroid hormone (PTH) level 3 months post-transplant (PTH ≥ 150 and < 150 pg/mL, respectively). High PTH was found to be an independent predictor for reduced kidney allograft function up to 3 years post-transplant. eGFR decreased by 11.4 mL/min (P < .001) and the odds of having an eGFR < 60 mL/min 3 years post-transplant were sixfold higher (P < .01) in the high compared to the low PTH group. Subgroup analysis based on eGFR 1 year post-transplant, presence of slow graft function (SGF), and transplant type revealed similar results. High PTH three months post-transplant was also independently associated with an increased risk for overall mortality and for death with a functioning graft (P < .05). pHPT three months post-renal transplantation is an independent predictor for a worse allograft function up to 3 years post-transplant and a risk factor for mortality. This relationship remains statistically significant after accounting for baseline allograft function, presence of SGF and serum mineral levels abnormalities.
Sections du résumé
BACKGROUND
Persistent hyperparathyroidism (pHPT) is frequently seen after transplantation contributing to post-transplant complications.
METHODS
We conducted a retrospective single center analysis to explore the relationship of early pHPT and long-term allograft outcome. Patients were divided into high (N = 153) and low (N = 252) PTH groups based on serum parathyroid hormone (PTH) level 3 months post-transplant (PTH ≥ 150 and < 150 pg/mL, respectively).
RESULTS
High PTH was found to be an independent predictor for reduced kidney allograft function up to 3 years post-transplant. eGFR decreased by 11.4 mL/min (P < .001) and the odds of having an eGFR < 60 mL/min 3 years post-transplant were sixfold higher (P < .01) in the high compared to the low PTH group. Subgroup analysis based on eGFR 1 year post-transplant, presence of slow graft function (SGF), and transplant type revealed similar results. High PTH three months post-transplant was also independently associated with an increased risk for overall mortality and for death with a functioning graft (P < .05).
CONCLUSIONS
pHPT three months post-renal transplantation is an independent predictor for a worse allograft function up to 3 years post-transplant and a risk factor for mortality. This relationship remains statistically significant after accounting for baseline allograft function, presence of SGF and serum mineral levels abnormalities.
Substances chimiques
Parathyroid Hormone
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14085Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Wolf M, Weir MR, Kopyt N, et al. A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation. Transplantation. 2016;100:184-193.
Evenepoel P. Recovery versus persistence of disordered mineral metabolism in kidney transplant recipients. Semin Nephrol. 2013;33:191-203.
Bhan I, Shah A, Holmes J, et al. Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'? Kidney Int. 2006;70:1486-1494.
Pilz S, Tomaschitz A, Drechsler C, et al. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J. 2010;31:1591-1598.
Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. Journal of the American Society of Nephrology: JASN. 2004;15:2208-2218.
van Ballegooijen AJ, Reinders I, Visser M, et al. Serum parathyroid hormone in relation to all-cause and cardiovascular mortality: the Hoorn study. The Journal of clinical endocrinology and metabolism. 2013;98:E638-E645.
Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008;52:519-530.
Deo R, Katz R, Shlipak MG, et al. Vitamin D, parathyroid hormone, and sudden cardiac death: results from the Cardiovascular Health Study. Hypertension. 2011;58:1021-1028.
Roodnat JI, van Gurp EA, Mulder PG, et al. High pretransplant parathyroid hormone levels increase the risk for graft failure after renal transplantation. Transplantation. 2006;82:362-367.
Araujo M, Ramalho JAM, Elias RM, et al. Persistent hyperparathyroidism as a risk factor for long-term graft failure: the need to discuss indication for parathyroidectomy. Surgery. 2018;163:1144-1150.
Pihlstrom H, Dahle DO, Mjoen G, et al. Increased risk of all-cause mortality and renal graft loss in stable renal transplant recipients with hyperparathyroidism. Transplantation. 2015;99:351-359.
Bleskestad IH, Bergrem H, Leivestad T, Hartmann A, Goransson LG. Parathyroid hormone and clinical outcome in kidney transplant patients with optimal transplant function. Clin Transplant. 2014;28:479-486.
Levi M, Ellis MA, Berl T. Control of renal hemodynamics and glomerular filtration rate in chronic hypercalcemia. Role of prostaglandins, renin-angiotensin system, and calcium. J Clin Investig. 1983;71:1624-1632.
Gwinner W, Suppa S, Mengel M, et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2005;5:1934-1941.
Lo Monte AI, Bellavia M, Damiano G, et al. A complex case of fatal calciphylaxis in a female patient with hyperparathyroidism secondary to end stage renal disease of graft and coexistence of haemolytic uremic syndrome. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. 2012;156:262-265.
Lo Monte AI, Bellavia M, Maione C, et al. Sistemic calciphylaxis and thrombotic microangiopathy in a kidney transplant patient: two mixing fatal syndromes? Med Hypotheses. 2012;79:74-75.
Barenbrock M, Hausberg M, Kosch M, Kisters K, Hoeks AP, Rahn KH. Effect of hyperparathyroidism on arterial distensibility in renal transplant recipients. Kidney Int. 1998;54:210-215.
Suwelack B, Gerhardt U, Witta J, Hillebrandt U, Hohage H. Effect of parathyroid hormone levels on carotid intima-media thickness after renal transplantation. Am J Hypertens. 2001;14:1012-1018.
Bellavia M, Gioviale MC, Damiano G, et al. Is secondary hyperparathyroidism-related myelofibrosis a negative prognostic factor for kidney transplant outcome? Med Hypotheses. 2011;77:557-559.
Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Eng J Med. 2002;346:580-590.
Haririan A, Nogueira JM, Zandi-Nejad K, et al. The independent association between serum uric acid and graft outcomes after kidney transplantation. Transplantation. 2010;89:573-579.
Endlich K, Massfelder T, Helwig JJ, Steinhausen M. Vascular effects of parathyroid hormone and parathyroid hormone-related protein in the split hydronephrotic rat kidney. J Physiol. 1995;483(Pt 2):481-490.
Jespersen B, Randlov A, Abrahamsen J, Fogh-Andersen N, Kanstrup IL. Effects of PTH(1-34) on blood pressure, renal function, and hormones in essential hypertension: the altered pattern of reactivity may counteract raised blood pressure. Am J Hypertens. 1997;10:1356-1367.
Trizna W, Edwards RM. Relaxation of renal arterioles by parathyroid hormone and parathyroid hormone-related protein. Pharmacology. 1991;42:91-96.
Massfelder T, Parekh N, Endlich K, Saussine C, Steinhausen M, Helwig JJ. Effect of intrarenally infused parathyroid hormone-related protein on renal blood flow and glomerular filtration rate in the anaesthetized rat. Br J Pharmacol. 1996;118:1995-2000.
Ellison DH, McCarron DA. Structural prerequisites for the hypotensive action of parathyroid hormone. Am J Physiol. 1984;246:F551-F556.
Helwig JJ, Musso MJ, Judes C, Nickols GA. Parathyroid hormone and calcium: interactions in the control of renin secretion in the isolated, nonfiltering rat kidney. Endocrinology. 1991;129:1233-1242.
Olgaard K, Lewin E, Bro S, Daugaard H, Egfjord M, Pless V. Enhancement of the stimulatory effect of calcium on aldosterone secretion by parathyroid hormone. Miner Electrolyte Metab. 1994;20:309-314.
Grant FD, Mandel SJ, Brown EM, Williams GH, Seely EW. Interrelationships between the renin-angiotensin-aldosterone and calcium homeostatic systems. J Clin Endocrinol Metabol. 1992;75:988-992.
Evenepoel P, Claes K, Kuypers DR, Debruyne F, Vanrenterghem Y. Parathyroidectomy after successful kidney transplantation: a single centre study. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2007;22:1730-1737.
Boom H, Mallat MJ, de Fijter JW, Paul LC, Bruijn JA, van Es LA. Calcium levels as a risk factor for delayed graft function. Transplantation. 2004;77:868-873.
Traindl O, Langle F, Reading S, et al. Secondary hyperparathyroidism and acute tubular necrosis following renal transplantation. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 1993;8:173-176.
Rostand SG, Drueke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int. 1999;56:383-392.
Floege J, Kim J, Ireland E, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2011;26:1948-1955.
Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31:607-617.
Egbuna OI, Taylor JG, Bushinsky DA, Zand MS. Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure. Clin Transplant. 2007;21:558-566.
Schwarz A, Mengel M, Gwinner W, et al. Risk factors for chronic allograft nephropathy after renal transplantation: a protocol biopsy study. Kidney Int. 2005;67:341-348.
Evenepoel P, Claes K, Kuypers D, Maes B, Bammens B, Vanrenterghem Y. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2004;19:1281-1287.
Wolf M, Molnar MZ, Amaral AP, et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. Journal of the American Society of Nephrology : JASN. 2011;22:956-966.
Rossaint J, Oehmichen J, Van Aken H, et al. FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J Clin Investig. 2016;126:962-974.
Singh S, Grabner A, Yanucil C, et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int. 2016;90:985-996.
Simic P, Kim W, Zhou W, et al. Glycerol-3-phosphate is a FGF23 regulator derived from the injured kidney. J Clin Investig. 2020.
Bjorkman MP, Sorva AJ, Tilvis RS. Elevated serum parathyroid hormone predicts impaired survival prognosis in a general aged population. Eur J Endocrinol. 2008;158:749-753.
Littbarski SA, Kaltenborn A, Gwiasda J, et al. Timing of parathyroidectomy in kidney transplant candidates with secondary hyperparathryroidism: effect of pretransplant versus early or late post-transplant parathyroidectomy. Surgery. 2018;163:373-380.
Jeon HJ, Kim YJ, Kwon HY, et al. Impact of parathyroidectomy on allograft outcomes in kidney transplantation. Transplant international : official journal of the European Society for Organ Transplantation. 2012;25:1248-1256.
Okada M, Hiramitsu T, Ichimori T, et al. Comparison of Pre- and Post-transplant Parathyroidectomy in Renal Transplant Recipients and the Impact of Parathyroidectomy Timing on Calcium Metabolism and Renal Allograft Function: A Retrospective Single-Center Analysis. World J Surg. 2020;44:498-507.